Literature DB >> 21921273

Cardiovascular pharmacogenomics.

Dan M Roden1, Julie A Johnson, Stephen E Kimmel, Ronald M Krauss, Marisa Wong Medina, Alan Shuldiner, Russell A Wilke.   

Abstract

Patients vary in their responses to drug therapy, and some of that variability is genetically determined. This review outlines general approaches used to identify genetic variation that influences drug response. Examples from specific therapeutic areas are presented, such as cholesterol management, arrhythmias, heart failure, hypertension, warfarin anticoagulation, and antiplatelet agents. A brief view of potential pathways to implementation is presented.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21921273      PMCID： PMC3201825          DOI： 10.1161/CIRCRESAHA.110.230995

Source DB:  PubMed          Journal:  Circ Res        ISSN： 0009-7330            Impact factor:   17.367


  145 in total

1.  Letter by Gurbel et al regarding article, "Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement".

Authors:  Paul A Gurbel; Udaya S Tantry; Alan R Shuldiner
Journal:  Circulation       Date:  2010-10-05       Impact factor: 29.690

Review 2.  Long QT syndrome: reduced repolarization reserve and the genetic link.

Authors:  D M Roden
Journal:  J Intern Med       Date:  2006-01       Impact factor: 8.989

3.  Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage.

Authors:  Russell A Wilke; Jason H Moore; James K Burmester
Journal:  Pharmacogenet Genomics       Date:  2005-06       Impact factor: 2.089

4.  Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure.

Authors:  Kersten M Small; Lynne E Wagoner; Albert M Levin; Sharon L R Kardia; Stephen B Liggett
Journal:  N Engl J Med       Date:  2002-10-10       Impact factor: 91.245

5.  Clopidogrel response variability and future therapies: clopidogrel: does one size fit all?

Authors:  Michelle O'Donoghue; Stephen D Wiviott
Journal:  Circulation       Date:  2006-11-28       Impact factor: 29.690

6.  Adrenergic signaling polymorphisms and their impact on cardiovascular disease.

Authors:  Gerald W Dorn
Journal:  Physiol Rev       Date:  2010-07       Impact factor: 37.312

7.  Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients.

Authors:  Aimée D C Paulussen; Ronaldus A H J Gilissen; Martin Armstrong; Pieter A Doevendans; Peter Verhasselt; Hubert J M Smeets; Eric Schulze-Bahr; Wilhelm Haverkamp; Günter Breithardt; Nadine Cohen; Jeroen Aerssens
Journal:  J Mol Med (Berl)       Date:  2004-02-04       Impact factor: 4.599

8.  Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study.

Authors:  Paul A Gurbel; Kevin P Bliden; Joseph DiChiara; Justin Newcomer; Willy Weng; Nagaraj K Neerchal; Tania Gesheff; Srivasavi K Chaganti; Amena Etherington; Udaya S Tantry
Journal:  Circulation       Date:  2007-06-11       Impact factor: 29.690

9.  KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST).

Authors:  Amber L Beitelshees; Yan Gong; Danxin Wang; Nicholas J Schork; Rhonda M Cooper-Dehoff; Taimour Y Langaee; Mark D Shriver; Wolfgang Sadee; Harm J Knot; Carl J Pepine; Julie A Johnson
Journal:  Pharmacogenet Genomics       Date:  2007-09       Impact factor: 2.089

Review 10.  Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives.

Authors:  Dominick J Angiolillo; Antonio Fernandez-Ortiz; Esther Bernardo; Fernando Alfonso; Carlos Macaya; Theodore A Bass; Marco A Costa
Journal:  J Am Coll Cardiol       Date:  2007-03-26       Impact factor: 24.094
View more
  27 in total

1.  Evidence for Clinical Implementation of Pharmacogenomics in Cardiac Drugs.

Authors:  Amy L Kaufman; Jared Spitz; Michael Jacobs; Matthew Sorrentino; Shennin Yuen; Keith Danahey; Donald Saner; Teri E Klein; Russ B Altman; Mark J Ratain; Peter H O'Donnell
Journal:  Mayo Clin Proc       Date:  2015-06       Impact factor: 7.616

Review 2.  Cardiovascular pharmacogenomics: current status and future directions.

Authors:  Dan M Roden
Journal:  J Hum Genet       Date:  2015-07-16       Impact factor: 3.172

3.  Biopsychosocial influence on shoulder pain: Rationale and protocol for a pre-clinical trial.

Authors:  Steven Z George; Roland Staud; Paul A Borsa; Samuel S Wu; Margaret R Wallace; Warren H Greenfield; Lauren N Mackie; Roger B Fillingim
Journal:  Contemp Clin Trials       Date:  2017-03-14       Impact factor: 2.226

Review 4.  Genetic determinants of response to cardiovascular drugs.

Authors:  Quinn S Wells; Jessica T Delaney; Dan M Roden
Journal:  Curr Opin Cardiol       Date:  2012-05       Impact factor: 2.161

Review 5.  Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementation.

Authors:  Frank S Ong; Joshua L Deignan; Jane Z Kuo; Kenneth E Bernstein; Jerome I Rotter; Wayne W Grody; Kingshuk Das
Journal:  Pharmacogenomics       Date:  2012-03       Impact factor: 2.533

Review 6.  Pharmacogenetics of Potassium Channel Blockers.

Authors:  Dan M Roden
Journal:  Card Electrophysiol Clin       Date:  2016-06

Review 7.  The genetics of pro-arrhythmic adverse drug reactions.

Authors:  Evmorfia Petropoulou; Yalda Jamshidi; Elijah R Behr
Journal:  Br J Clin Pharmacol       Date:  2014-04       Impact factor: 4.335

Review 8.  Pharmacogenetics of heart failure.

Authors:  Luisa Mestroni; Rene L Begay; Sharon L Graw; Matthew R G Taylor
Journal:  Curr Opin Cardiol       Date:  2014-05       Impact factor: 2.161

9.  Characterization of statin dose response in electronic medical records.

Authors:  W-Q Wei; Q Feng; L Jiang; M S Waitara; O F Iwuchukwu; D M Roden; M Jiang; H Xu; R M Krauss; J I Rotter; D A Nickerson; R L Davis; R L Berg; P L Peissig; C A McCarty; R A Wilke; J C Denny
Journal:  Clin Pharmacol Ther       Date:  2013-10-04       Impact factor: 6.875

Review 10.  Pharmacogenetics and cardiovascular disease--implications for personalized medicine.

Authors:  Julie A Johnson; Larisa H Cavallari
Journal:  Pharmacol Rev       Date:  2013-05-17       Impact factor: 25.468
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.